ArticleInternational urology and nephrology2025
Reassessing finerenone's role in IgA nephropathy: methodological and clinical considerations.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This letter addresses the study "Effectiveness and Safety of Finerenone in the Treatment of IgA Nephropathy Patients" by Qingqing Gao, which investigates finerenone as adjunct therapy in IgA nephropathy. While the study offers promising insights, key methodological limitations-including lack of randomization, blinding, and small sample size-raise concerns regarding selection bias and external validity. Additionally, the omission of important clinical parameters such as blood pressure and inflammatory markers limits the scope of safety monitoring. The letter emphasizes the need for larger, multicenter, randomized controlled trials with improved monitoring strategies, including MEST-C scoring, to enhance diagnostic accuracy and outcome interpretation. Despite the study's strengths in reporting UACR reduction and stable eGFR, a more rigorous research design is essential to fully evaluate finerenone's long-term efficacy and safety in this patient population.
Indexed as
Identifiers
40471528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.